794 related articles for article (PubMed ID: 8719548)
21. Immunosuppressive treatment of Berger's disease.
Faedda R; Pirisi M; Satta A; Bosincu L; Bartoli E
Clin Pharmacol Ther; 1996 Nov; 60(5):561-7. PubMed ID: 8941029
[TBL] [Abstract][Full Text] [Related]
22. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
[TBL] [Abstract][Full Text] [Related]
23. Treatment of membranous lupus nephritis.
Moroni G; Maccario M; Banfi G; Quaglini S; Ponticelli C
Am J Kidney Dis; 1998 Apr; 31(4):681-6. PubMed ID: 9531186
[TBL] [Abstract][Full Text] [Related]
24. Longterm followup of childhood lupus nephritis.
Hagelberg S; Lee Y; Bargman J; Mah G; Schneider R; Laskin C; Eddy A; Gladman D; Urowitz M; Hebert D; Silverman E
J Rheumatol; 2002 Dec; 29(12):2635-42. PubMed ID: 12465165
[TBL] [Abstract][Full Text] [Related]
25. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.
Illei GG; Yarboro CH; Kuroiwa T; Schlimgen R; Austin HA; Tisdale JF; Chitkara P; Fleisher T; Klippel JH; Balow JE; Boumpas DT
Rheumatology (Oxford); 2007 Jun; 46(6):952-6. PubMed ID: 17317716
[TBL] [Abstract][Full Text] [Related]
26. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis.
Conlon PJ; Fischer CA; Levesque MC; Smith SR; St Clair EW; Allen NB; Fleming JA; Howell DN
Clin Nephrol; 1996 Sep; 46(3):170-5. PubMed ID: 8879851
[TBL] [Abstract][Full Text] [Related]
27. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience.
El-Husseini A; El-Basuony F; Mahmoud I; Sheashaa H; Sabry A; Hassan R; Taha N; Hassan N; Sayed-Ahmad N; Sobh M
Nephrol Dial Transplant; 2005 Nov; 20(11):2433-8. PubMed ID: 16204303
[TBL] [Abstract][Full Text] [Related]
28. Frequency of recurrent lupus nephritis among ninety-seven renal transplant patients during the cyclosporine era.
Stone JH; Millward CL; Olson JL; Amend WJ; Criswell LA
Arthritis Rheum; 1998 Apr; 41(4):678-86. PubMed ID: 9550477
[TBL] [Abstract][Full Text] [Related]
29. Cyclosporine A in treatment of membranous lupus nephropathy.
Hu W; Liu Z; Shen S; Li S; Yao X; Chen H; Li L
Chin Med J (Engl); 2003 Dec; 116(12):1827-30. PubMed ID: 14687467
[TBL] [Abstract][Full Text] [Related]
30. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis.
Szeto CC; Kwan BC; Lai FM; Tam LS; Li EK; Chow KM; Gang W; Li PK
Rheumatology (Oxford); 2008 Nov; 47(11):1678-81. PubMed ID: 18753192
[TBL] [Abstract][Full Text] [Related]
31. Lupus nephritis in children.
Hafeez F; Tarar AM; Saleem R
J Coll Physicians Surg Pak; 2008 Jan; 18(1):17-21. PubMed ID: 18452662
[TBL] [Abstract][Full Text] [Related]
32. [Survival of patients with diffuse glomerulonephritis in disseminated lupus erythematosus treated with a combination of anticoagulants, corticosteroids and immunosuppressants].
Belovezhdov N; Dimitrova V
Vutr Boles; 1987; 26(1):21-7. PubMed ID: 3590722
[TBL] [Abstract][Full Text] [Related]
33. [Immunosuppressive therapy of glomerulonephritis--controlled studies].
Ferrari P; Frey FJ
Ther Umsch; 1993 Feb; 50(2):119-29. PubMed ID: 8456416
[TBL] [Abstract][Full Text] [Related]
34. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial.
Hofstra JM; Branten AJ; Wirtz JJ; Noordzij TC; du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2010 Jan; 25(1):129-36. PubMed ID: 19666912
[TBL] [Abstract][Full Text] [Related]
35. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study.
Wang HY; Cui TG; Hou FF; Ni ZH; Chen XM; Lu FM; Xu FF; Yu XQ; Zhang FS; Zhao XZ; Zhao MH; Wang GB; Qian JQ; Cai GY; Zhu TY; Wang YH; Jiang ZP; Li YN; Mei CL; Zou WZ;
Lupus; 2008 Jul; 17(7):638-44. PubMed ID: 18625636
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of acute systemic lupus erythematosus with intravenous infusions of cyclophosphamide. Value and limitations].
De Bandt M; Goycochea MV; Meyer O; Delahousse M; Palazzo E; M'Bappé P; Kahn MF
Ann Med Interne (Paris); 1994; 145(2):75-87. PubMed ID: 8024184
[TBL] [Abstract][Full Text] [Related]
37. [Cyclosporin therapy of patients with systemic lupus erythematosus].
Gergely P
Orv Hetil; 1994 Nov; 135(47):2591-5. PubMed ID: 7824258
[TBL] [Abstract][Full Text] [Related]
38. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide.
Donadio JV; Holley KE; Ferguson RH; Ilstrup DM
N Engl J Med; 1978 Nov; 299(21):1151-5. PubMed ID: 309095
[TBL] [Abstract][Full Text] [Related]
39. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
[TBL] [Abstract][Full Text] [Related]
40. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study.
Fischer-Betz R; Chehab G; Sander O; Vordenbäumen S; Voiculescu A; Brinks R; Schneider M
J Rheumatol; 2012 Nov; 39(11):2111-7. PubMed ID: 22984276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
